Xencor and UCLA have established a streamlined framework to select promising biology, perform collaborative research and license intellectual property.
Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures, such as bispecific antibodies and engineered cytokines, or amplification of natural immune functions, such as extending circulating half-life or enhancing immune cell cytotoxicity.
Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates for the treatment of patients with life-threatening and debilitating diseases.
Two of these antibodies have been approved by the US FDA, one for the treatment of patients with rare blood disorders and the other for an aggressive form of non-Hodgkin lymphoma.
The UCLA Technology Development Group, the campus' gateway to innovation, research and entrepreneurship, will work with faculty to propose potential antibody drug candidates. For selected candidates, the collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.
Currently, 20 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action.
UCLA Technology Development Group promotes UCLA innovation, research, education and entrepreneurship to benefit society.
Working with UCLA TDG helps facilitate the translation of UCLA discoveries into new products and services that create economic value to support UCLA's scholarly and educational missions.
The UCLA TDG office manages a large portfolio of technologies and license agreements and has a rich history of startup company formation.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial